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ABSTRACT: Cluster headache is a rare and severe pain syndrome with elusive patho-
physiology. Serotonin pathways within the brainstem may be implicated in cluster
headache with seasonal affective disorder and a subset of cranial nerve neuralgias. We
describe and chronicle a syndrome consisting of cluster headache, seasonal affective
disorder, with associated trigeminal, glossopharyngeal, superior laryngeal neuralgias
in an 11-year-old female. Pharmacologic interventions for this patient were examined
in conjunction with current classification, location and function of serotonin receptors.
Etiology is postulated as mixed cranial nerve excitation via endogenous 5-HT (agonist)
activity of 5-HT3 receptors within the nucleus tractus solitarius and trigeminal tract
nucleus.
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Introduction
Serotonin is a major neurotransmitter known to mediate mood, sati-
ety, and pain perception. A seasonal or other shift in sunlight can
trigger a decline in melatonin resulting in diminished serotonin pro-
duction.1 Low serotonin levels have been strongly implicated in cluster
headache (CH) and seasonal affective disorder (SAD).2 SAD and CH
have been associated with a shared seasonal onset.3 A seasonal trigger
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may be suggested in a subset of facial cranial neuralgias.4 The latter
neuralgias often respond to anti-depressant therapy and involve cra-
nial nerves V, IX, X or XI.5 Notably, both the trigeminal tract nucleus,
subserving cranial nerve V, and the adjacent nucleus tractus solita-
rius (NTS), subserving cranial nerves IX, X and XI are densely packed
with serotonin receptors.6
Triggers occur with many of cranial nerve neuralgias, especially tri-
geminal neuralgia, and remain specific for the individual patient. Cra-
nial nerve neuralgias sometimes occur in pairs.5,7 The chronicity of
CH and SAD has been associated with a shared seasonal onset.3 The
combination of CH, SAD, and cranial nerve neuralgias has not been
previously reported. We describe such a case occurring in a pre-adoles-
cent girl.
Cluster headache (CH) is considered the most painful of headaches
currently classified.8 CH occurs more frequently in males (5:1–9:1).
The peak age of onset is 20–29. The childhood presentation of CH may
be misinterpreted, resulting in under reporting of the illness within
the pediatric population.9 Ten to twenty percent of CH patients exhibit
the chronic form defined as recurrent pain greater than one year in
duration with remissions of less than 14 consecutive days.4 The in-
tense pain is habitually unilateral at or around the orbit in a V1 dis-
tribution. Nasal stuffiness and hyperactivity with head banging or
rubbing accompanies the onset of pain. Typically ocular Horner’s syn-
drome with supraorbital swelling, ipsilateral ptosis, miosis, tearing,
and conjunctiva injection follows the pain episode. Tearing may pre-
cede the pain episode.4 Speech remains intact. In a minority of cases
structural abnormalities may be identified by neuroimaging. CH at-
tacks frequently occur within the same hours of the day over the
course of several weeks.8 CH pain first occurs in the daily cycle at the
onset of REM sleep, 1–1 1/2 hours after retiring. Sleep deprivation has
been effective in delaying CH attacks into the early morning hours but
not eliminating the nocturnal attack. Decreased levels of serotonin
and nocturnal melatonin are reported in cluster headache patients.
Seasonality of this pain syndrome has been described and correlates
with the active phase in SAD patients.1
SAD is typically characterized by recurrent depression with a fall/
winter onset, hypersomnia and overeating.10 Five to ten percent of the
U.S. population has symptomatology suggestive of the disorder, and
up to 3%–4% of U.S. school age children may suffer from SAD.11 Sero-
tonin levels are decreased in SAD patients.2 5-HT7 serotonin receptors
are thought to play a role in circadian rhythms.6
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Trigeminal neuralgia involves the excitation of one or more of the
three branches of the trigeminal nerve. Less than 5% of trigeminal
neuralgias involve V1.
4 The pain episodes are commonly unilateral and
are of sudden onset with short duration. Repetitive episodes occur
daily. The pain does not cross to the contralateral side. Carbamaze-
pine, Phenytoin and Clonazepam have shown clinical efficacy, and are
withdrawn after a short course. Remissions occur spontaneously and
may last for months to years. Trigeminal neuralgia occurs more fre-
quently in women (3:2) and is 100 times more common than glosso-
pharyngeal neuralgia.5 Trigeminal neuralgia may accompany glosso-
pharyngeal neuralgia in one out of every eight cases.7
Glossopharyngeal neuralgia involves unilateral irritation of the
ninth cranial nerve (IX). Sensory vagal nerve afferents are also sus-
pected in this pain syndrome. Symptomatology includes painful, cut-
ting, stabbing, shooting or sharp sensations to the throat. Throat pain
can last minutes to hours. Ipsilateral ear sensations include “fullness”
or “dragging” and usually occur prior to the pain episode in the throat.
A foreign body feeling on the ipsilateral tonsil during or prior to pain
onset has been reported.7 Triggers include swallowing, talking, yawn-
ing, and coughing.5 Activation of the dorsal motor nucleus of the vagus
nerve (X) during a glossopharyngeal neuralgia episode has resulted in
bradycardia and syncope.7,4
Superior laryngeal neuralgia is a rare pain syndrome associated
with lowered pitch and pain on vocalization, lateral throat pain occur-
ring within the submandibular region. Pain may also present under
the ear. Pain episodes can last minutes to days. Activation of the supe-
rior laryngeal nerve occurs via the general visceral afferent compo-
nent of the vagus nerve. Sufferers have identified triggers.5
Case Report
D. is an 11-year-old female presenting with a three-year history of chronic
cluster headache and SAD. Accompanying neuralgias included trigeminal
neuralgia, glossopharyngeal neuralgia, and superior laryngeal neuralgia. Her
symptomatology increased with seasonal decrease in day length. CH first pre-
sented upon relocation from Georgia (33.47 N latitude) to Michigan (42.32 N
latitude) in late summer, during the child’s ninth year. The chronic form of
CH was established after unsuccessful withdrawal of maintenance medication
in the second year. Triggers have included Dihydroergotamine mesylate (Mi-
granal), repetitive but undeniable yawning, and inhalation of CO2. Pharmaco-
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logic outcomes for this patient were examined in conjunction with current
classification, location and function of serotonin receptors.
Patient History
Patient D. was born via induction at 43 weeks gestation. As a toddler she
experienced gross motor and language delays speaking 3–word sentences at
age 5 and toe walking until age 8. After speech development, complaints of
urinary urgency, fear of poisoning, and fear of death occurred on a fall/winter
cycle. At age 5 she developed repetitive spitting behavior and complained of
occasional head pain. Anxiety and physical symptoms progressively increased
each fall/winter season. All school photos taken in the fall/winter seasons
show supraorbital swelling and facial asymmetry on the left. At 7 years 8
months the Wechsler’s Intelligence Scale III for children was administered.
The assessment revealed a full scale IQ of 126; with verbal and performance
scores of 131 and 116 respectively. At age 8 patient D. reported a transient
loss of color vision. The loss of color vision correlated with “seeing harmful
snakes and spiders” and right sided chest pain with increased pulse. Fluvoxa-
mine (Luvox) 25mg was instituted. A good response from Fluvoxamine oc-
curred without dose elevation for two years. Family history includes bipolar
disorder, unipolar depression, obsessive compulsive disorder, anorexia ner-
vosa, and tic douloureux.
The first “active phase” for CH occurred in the fall/winter of 1997. At age 9
the patient relocated from Georgia (33.47 N latitude) to Michigan (42.32 N
latitude). She was slowly tapered off Fluvoxamine over the course of one
month, ending on October 31. “Terrible head pain” occurred seven days after
her last dose of Fluvoxamine. Twenty-one days post Fluvoxamine therapy,
patient developed left-sided cluster headaches, Horner’s syndrome and poly-
dipsia during the pain episode. Brain MRI and MRA were negative for related
pathology. After a trial course of Indomethacin failed to alter the headache
course, standard induction therapy with Prednisone 40mg/day for 4days was
instituted. Fluvoxamine 25mg/day was restarted as maintenance therapy. Ox-
ygen at 4liters/min via nasal cannula constituted abortive therapy. Once sta-
bilized, the patient further recovered in Florida at 26.52(N) latitude. Her last
reported CH of the first active phase was on December 31, 1997.
In late June 1998 Fluvoxamine was tapered over 5 weeks. Concurrent, pro-
gressive dose replacement equivalent of Fluoxetine (Prozac) therapy at 20mg/
day was completed by August. The first CH occurred on day 15 of the Fluvoxa-
mine taper. The CH pattern accelerated, bilateral facial flushing with pain or
numbness was noted during or shortly after a pain episode. The antihista-
mine Periactin (at 4mg/day) provided no relief. Migranal nasal spray was
added to the patient’s CH protocol, for abortive therapy. Ergotamine (Migra-
nal) has serotonin antagonist properties.12 A single dose of Migranal during a
CH episode produced acute symptoms. These included: sudden nausea with
vomiting, bilateral facial flushing, increased heart rate (140/min), sore throat
with foreign body sensation, pain upon vocalizing, “narrowing of throat” and
“dragging string” through ear canal sensation (right side), and the inability of
the patient to turn her head to the left. Her CHs occurred at the same times
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of day as in the previous season. CH and cranial neuralgia episodes continued
to increase. The patient was removed from Fluoxetine, completing 12 weeks
of therapy. Fluvoxamine 25mg was re-instituted and 4 weeks later CH, with
accompanying cranial nerve neuralgias V, IX, X, and XI resolved. A repeat
brain MRI/MRA was performed with incidental finding of a left cerebellar
hemisphere development venous anomaly (venous angioma). MRI/MRA of the
neck was unremarkable.
The patient remained asymptomatic on Fluvoxamine 25mg/day until mid-
November 1998. Repeated episodes over a six week period included: hyperten-
sion, chest pain, back pain, bilateral facial flushing, increased facial tempera-
ture/facial pain, extreme sudden nausea with/without vomiting, dizziness,
throat pain, “voice pain,” half of tongue base “disconnected,” and “string drag-
ging” in ear, escalated in number and acuity. Yawning was identified as a
trigger for trigeminal neuralgia at V2 (facial flushing) cascading into glosso-
pharyngeal neuralgia and superior laryngeal neuralgia. Cranial neuralgias
would often occur shortly before or after a cluster headache episode. A visual
decrease in color intensity but not hue was reported during pain episodes.
Triggers included Migranal, repetitive but undeniable yawning and inhala-
tion of CO2. In the course of fall/winter the patient was seen in the ER three
times for pain episodes related to cluster headache with cranial neuralgias.
Sumatriptan nasal spray and oral preparation were initially used with good
relief, but over time chest pain and rebound neuralgias occurred with short-
ness of breath. Three courses of IV steroid treatment were given without ben-
efit. Neurontin 300mg/tid was prescribed but discontinued on day 4, due to
ataxia, muscle weakness and persistent neuralgias. Fluvoxamine was in-
creased to 50mg/day. Carbamazepine (Tegretol) was given at a starting dose
of 100/bid then substituted for Tegretol XR 200mg/bid. Anti-seizure therapeu-
tic levels were reached and maintained at this dose. CH symptomatology in-
creased with progressive decrease in day length, following the SAD predictive
model.3 Patient D. was relocated to Florida (26.52 N. latitude) for two weeks.
Treatment upon return to Michigan included 10,000 lux light box therapy
bid. Symptomatology continued to increase with CH and cyclic cranial nerve
neuralgia episodes. In February the patient was relocated to the British West
Indies (19.30 N. latitude) for one week with significant improvement. Symp-
tomatology accelerated upon return to Michigan but gradually decreased with
increasing day length. Removal from Tegretol ensued by slow taper ending
May 1. The patient remained asymptomatic on Fluvoxamine 50mg/d, during
the spring/summer season, with the exception of a single episode of trigeminal
and glossopharyngeal neuralgia, occurring after three dark and raining days
in April.
In mid-September 1999, sudden nausea preceded the almost daily CH and
cranial nerve neuralgia episodes. In early November, Fluvoxamine 50mg/day
was gradually increased to 100mg/day. Symptomatology continued to increase
in frequency. Amitriptyline (Elavil) with escalating dosage to achieve 50mg/
day was instituted in mid-November. Ten days following augmentation of se-
lective serotonin reuptake inhibitor (SSRI) therapy with tricyclic antidepres-
sant therapy (TCA) the patient was asymptomatic. At one-month post-TCA
therapy the patient reported one episode of glossopharyngeal neuralgia. EKG
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and Amitriptyline levels were monitored. The patient retreated to Florida for
3 weeks beginning on December 16, 1999 and remained asymptomatic upon
return to Michigan.
Discussion
Postulated Mechanism of Syndrome
High densities of 5-HT3 receptors are found in the NTS, trigeminal
tract nucleus, dorsal vagal complex, and the hippocampus in man.6
Rapid depolarization and subsequent excitation of central nervous
system serotonin neurons within the NTS, trigeminal nucleus and
dorsal vagal complex is hypothesized as the mechanism for the CH
variant described.
Depolarization of 5-HT3 receptors can occur through the introduc-
tion of Na+, K+, and Ca++ ions or via endogenous 5-HT agonist activ-
ity.6 Endogenous 5-HT that exceeds physiologic neuronal limits (a 5-
HT spike) acts as a 5-HT3 receptor agonist. Extracellular serotonin
agonist activity is commonly seen in chemotherapy patients. Upon
Cisplatinum administration endogenous 5-HT is introduced to 5-HT3
receptors within the NTS, from enterochromaffin cells in the small
intestine. The sudden availability of 5-HT in excess of extracellular
concentrations seen in neuronal uptake and synthesis regulation acts
as an agonist exciting the NTS and eliciting sudden emesis commonly
associated with most antineoplastic agents.13
Blockade of serotonin uptake by a serotonin antagonist will produce
a significant and sudden increase in endogenous 5-HT. Migranal (di-
hydroergotamine) is a serotonin antagonist. Migranal’s serotonergic
activity is postulated to precipitate the activation of 5-HT3 receptors
within the NTS and trigeminal tract nucleus, via an endogenous 5-
HT spike.
Cranial nerves V, IX, X, XI can be activated by 5-HT3 receptors
within the NTS and trigeminal tract nucleus.14 Rapid depolarization
of the lower NTS subserving the general visceral afferent component
of the glossopharyngeal, accessory and/or dorsal vagus nerves may re-
sult in cranial nerve neuralgias of IX, X, and/or XI. Rapid depolariza-
tion of the lower and middle tracts of the trigeminal tract nucleus may
respectively result in the excitation of the first and second branches
of the trigeminal nerve leading to CH and trigeminal neuralgia. 5-HT6
and 5-HT7 receptors in the hippocampus and hypothalamus may play
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a role in the patient’s yawning trigger and altered circadian rhythm
respectively.6 Taste, subserved by the upper portion of the NTS, was
not altered in this patient. (See Figure 1)
Conclusion
Activation of 5-HT3 serotonin receptors within the NTS and trigemi-
nal tract nucleus via endogenous 5-HT agonist activity is postulated
as the mechanism and neuroanatomic basis of the described serotonin
mediated CH variant.
Decreased extracellular serotonin noted in SAD patients may create
a seasonal decrease in baseline serotonin. Endogenous 5-HT agonist
activity is more readily achieved in the fall/winter months when di-
minished levels of baseline serotonin occur.
Management of this syndrome includes down-regulation of seroto-
nin receptors with SSRI therapy augmented by TCA therapy. A de-
creased firing rate of 5-HT3 serotonin neurons within the NTS and
trigeminal tract nucleus with concurrent/compensatory increases in
baseline extracellular 5-HT was achieved with Fluvoxamine and Ami-
triptyline.
Fluvoxamine proved superior to Fluoxetine at corresponding doses.
Both Fluvoxamine and Fluoxetine inhibit serotonin reuptake at 5-HT3
receptors. This increases extracellular serotonin, down-regulating the
5-HT3 receptor. Fluvoxamine additionally inhibits serotonin reuptake
at 5-HT1A receptors (β adrenergic receptors).15 This further increases
extracellular serotonin levels augmenting the down-regulation of 5-
HT3 receptors. By raising the activation threshold of 5-HT3 receptors
in the NTS and the trigeminal tract nucleus we postulate SSRI’s alone
or augmented with TCA’s may reduce the aberrant 5-HT agonist acti-
vation.
Summary
CH is rarely diagnosed in children.9 We examine a pediatric case of
CH, SAD, and accompanying cranial nerve neuralgias. Location and
function of 5-HT3 receptors in addition to neuroanatomy of cranial
nerves V, IX, X, XI at their termination point within the trigeminal
tractus nucleus and NTS is reviewed. Etiology for this CH variant is
hypothesized as 5-HT3 serotonin receptor activation of NTS and tri-
Child Psychiatry and Human Development52
Figure 1. NTS and Trigeminal Tract Nucleus 5 HT3 Receptor Distribution,
Pathways and Related Symptomatology
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geminal tractus nucleus within the brainstem. Pharmaceutical man-
agement of this serotonin mediated syndrome with SSRI (Fluvoxa-
mine) maintenance therapy in addition to TCA therapy (Amitriptyline)
during the active phase is outlined. The treatment course is proactive,
year round, and adjusted for the length of day. Pain management with
oxygen and travel to decreasing northern latitudes appears beneficial.
Should the need arise, 5-HT3 antagonist therapy, with Ondansetron
(Zofran) to counter acute activation episodes of the NTS and trigemi-
nal tract nucleus, might be considered. The future challenge for clini-
cians and researchers alike will be in fully understanding the bio-
chemical pathways, circadian rhythms, and seasonal shifts, leading to
such extraordinary pain syndromes, depression and anxiety disorders.
Such knowledge could eliminate or minimize symptomatology by pre-
empting serotonin-mediated disorders with proactive treatment plans,
in susceptible populations.
References
1. Costa A, Leston JA, Cavallini A, Nappi G. Cluster Headache and peroidic affective
illness: common chronobiological features. Functional Neurology 1998; 13:263–271.
2. Meluzzi A, Gecele M, Franacesetti G, Bongioanni P. Serotonin, the Light-Dark Cy-
cle, and Behavior: Platelet MAO Activity in Normal and Depressed Subjects Before
and After Light Therapy. In: Nappi G, Sandrani G, Giuseppe M, Bono G, Martig-
noni E, Micieli G, eds. Headache and Depression: Serotonin Pathways as a Common
Clue. New York: Raven Press, 1991:87–107.
3. Micieli G, Sjaastad O, Leston JA, et al. Cluster Headache Temporal Patterns and
Environmental Changes: A prospective, Multinational, Multicentric Study. In:
Nappi G, ed. Headache and Depression:Serotonin Pathways as a Common Clue.
New York: Raven Press, 1991:133–144.
4. Lance JW, Goadsby PJ. Cluster Headache and Related Conditions. In: Lance JW,
Goadsby PJ, eds. Mechanism and Management of Headache. Vol. 6. Cambridge:
The University Press, 1993:176–205.
5. Solomon S, Lipton R. Facial Pain. Neurologics Clinics 1990; 8:919–928.
6. Kennett G. Serotonin Receptors and their Function. InterNet www.tocris.com/sero-
tonin.htm: Tocris, 1997:1–16.
7. Rushton JG, Stevens C, Miller RH. Glossopharyngeal (Vasoglossopharyngeal) Neu-
ralgia. Arch Neurol 1981; 38:201–205.
8. Lewis TA, Solomon GD. Advances in cluster headache management. Cleveland
Clinic Journal of Medicine 1996; 63:237–244.
9. McNabb S, Whitehouse W. Cluster headache-like disorder in childhood. Arch Dis
Child 1999; 81:511–512.
10. Rosenthal NE, Sack DA, Christian G, et al. Seasonal Affective Disorder: A Descrip-
tion of the Syndrome and Preliminary Findings with Light Therapy. Arch Gen Psy-
chiatry 1984; 41:72–80.
11. Meesters Y. Case Study: Dawn Simulation as Maintenance Treatment in a Nine-
Year-Old Patient with Seasonal Affective Disorder. J Am Acad Child Adolesc Psy-
chiatry 1998; 37:986–988.
Child Psychiatry and Human Development54
12. Fritze J, Unsorg B, Lanczik M. Interaction between carbamazepine and fluvoxa-
mine. Acta Psychiatr Scand 1991; 84:583–584.
13. PDR. Physicians Desk Reference. In: Arky R, ed. PDR 52nd edition 1998. Vol. 52.
Montvale, NJ: Medical Ecomonimcs Company, 1998:1962.
14. Craigmyle M. The Mixed Cranial Nerves. In: Craigmyle M, ed. The Mixed Cranial
Nerves. New York: John Wiley & Sons, 1985:1–96.
15. Fuller R. Serotonin uptake inhibitors: uses in clinical therapy and in laboratory
research. Prog Drug Res 1995; 45:167–204.
